Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Hodgkin Disease 1

Interventions

Cyclophosphamide 18fludarabine phosphate 16Rituximab 16Etoposide 16Peripheral Blood Stem Cell Transplantation 14Brentuximab Vedotin 14fludarabine 11Whole-Body Irradiation 11Nivolumab 11Mycophenolic Acid 11Bendamustine Hydrochloride 11Tacrolimus 10Melphalan 10Filgrastim 9Gemcitabine 8Carboplatin 8Ifosfamide 7Cytarabine 7Cyclosporine 7Busulfan 7pembrolizumab 6Lenalidomide 6Doxorubicin 6Prednisone 5Everolimus 5Antilymphocyte Serum 5Alemtuzumab 5Vinblastine 4Methotrexate 4Mesna 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Hodgkin Disease × Insulin Infusion Systems × Clear all
NCT06090864 2025-10-20

ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Recruiting
31 enrolled
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡